<DOC>
	<DOC>NCT01358019</DOC>
	<brief_summary>The primary objective of this study is to examine a recommended dose for subsequent phase trial(s), by the observation of the safety and toxicity profiles of LY2523355 in patients with advanced and/or metastatic cancer. The secondary objectives are to study the pharmacokinetics and antitumor effect.</brief_summary>
	<brief_title>A Study of LY2523355 in Patients With Solid Cancer</brief_title>
	<detailed_description />
	<criteria>Histological and/or cytological evidence of solid tumors A diagnosis of advanced and/or metastatic solid tumors Patients who are refractory to standard therapy or for which no proven effective therapy exists Written informed consent Appropriate bone marrow, hepatic and renal functions ECOG PS =&lt; 1 Have serious preexisting complication Have active infection which requires intravenous antibiotics Have symptomatic central nervous system metastases Have current acute or chronic leukemia Have had an autologous or allogenic hematopoietic stem cell transplantation Have active multiple cancers</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>